
A Most Favored National Policy for Pharma Drugs Makes Sense
"Most favored nation" pricing can help make America's pharmaceutical marketplace more competitive.
It is not surprising that President Trump issued a May 12, 2025 executive order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which represents the administration’s efforts to lower prescription drug prices. This action uses what is known as “most favored nation” pricing to link the price of selected U.S. pharmaceutical drugs in America to countries where the same drugs are sold for less. The order extends beyond Medicare Part B drugs and will likely target lucrative expensive medications like GLP-1 drugs (known for weight management et al). Also targeted will be the ability of Big Pharma to set its own prices.
It is sensible both economically and politically.
As an economist, I believe that the marketplace is the best way to solve most pricing problems. Unfortunately, America’s pharmaceutical industry, and medical care in general, are not competitive marketplaces. Regulations, industry consolidation, and third-party insurance all lead to extraordinarily high prices for medications. Expensive to begin with, the cost of drug development has increased by a factor of 5 when accounting for costs of capital and failures. From 2008 to 2019, the ratio of R&D spending to total sales increased from 11.9% to 17.7%. Once launched though, the marginal cost of manufacturing most drugs is extraordinarily low. In many cases a single capsule costs only pennies to make. In a truly competitive market, where marginal revenue and marginal cost equate in the long run, many medicines would be extraordinarily inexpensive.
Economic Dynamism

Automated Detection of Emotion in Central Bank Communication: A Warning
Can LLMs help us better understand the role of emotion in central bank communication?

Defending Technological Dynamism & the Freedom to Innovate in the Age of AI
Human flourishing, economic growth, and geopolitical resilience requires innovation—especially in artificial intelligence.

Firm Investment and the User Cost of Capital: New U.S. Corporate Tax Reform Evidence
This working paper analyzes the Tax Cuts and Jobs Act of 2017 to examine how corporate tax reform impacts rates of investment.

It’s Not Easy, but We Can All Learn to Think like Adam Smith
To truly understand what a dynamic economy requires, we would do well to recover the 18th-century sensibility that understood dynamism as a social and cultural phenomenon as much as an economic one.

Escape From New York
With Mamdani rising in New York, Texas can now offer New York’s leading businesses a package deal: relocate to Texas and list on the TXSE. Call it the Texas Two-Step.

Exploring the Future of Latin America and US Relations
The authors examine the promises and perils of the Trump administration and the new governments in Latin America, and look forward to a renewed dialogue with U.S.-based scholars at this moment of opportunity.